April 16, 2018 / 1:40 PM / 6 days ago

BRIEF-Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab

April 16 (Reuters) - Apellis Pharmaceuticals Inc:

* APELLIS PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1B OPEN LABEL STUDY OF APL-2 IN PNH PATIENTS NOT PREVIOUSLY TREATED WITH ECULIZUMAB

* APELLIS PHARMACEUTICALS INC - TO DATE, APL-2 HAS GENERALLY BEEN WELL-TOLERATED IN PATIENTS

* APELLIS PHARMACEUTICALS INC - EXPECTS TO REPORTING FURTHER UPDATES TO ONGOING PADDOCK TRIAL IN JUNE

* APELLIS - IN H2 2018, PLANS TO INITIATE A PHASE 3 TRIAL IN 70 PATIENTS WITH PNH VERSUS TREATMENT WITH APL-2 MONOTHERAPY TO TREATMENT WITH ECULIZUMAB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below